Supernus Pharmaceuticals develops and commercializes products for central nervous system diseases. Commercial products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. Product candidates include SPN-830, SPN-817, SPN-820, SPN-443, SPN-446, and SPN-448. The company markets products through wholesalers, specialty pharmacies, and distributors. It was incorporated in 2005 and is headquartered in Rockville, Maryland.
| Indicator | Value |
|---|---|
| PER | 32.4 |
| EV/EBITDA | 13.7 |
| Price/Free Cash Flow' | 14.0 |
| ROIC | 16.1% |
| Net Debt/EBITDA | -0.2 |